Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Income towards Parent Company (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Income towards Parent Company for 11 consecutive years, with -$4.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income towards Parent Company rose 13.81% year-over-year to -$4.2 million, compared with a TTM value of -$18.2 million through Sep 2025, up 0.91%, and an annual FY2024 reading of -$20.0 million, up 4.1% over the prior year.
  • Income towards Parent Company was -$4.2 million for Q3 2025 at Lisata Therapeutics, up from -$4.7 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at -$3.0 million in Q4 2023 and bottomed at -$6.2 million in Q1 2023.
  • Average Income towards Parent Company over 3 years is -$4.7 million, with a median of -$4.7 million recorded in 2025.
  • The sharpest move saw Income towards Parent Company tumbled 51.89% in 2024, then grew 13.81% in 2025.
  • Year by year, Income towards Parent Company stood at -$3.0 million in 2023, then crashed by 51.89% to -$4.6 million in 2024, then increased by 7.83% to -$4.2 million in 2025.
  • Business Quant data shows Income towards Parent Company for LSTA at -$4.2 million in Q3 2025, -$4.7 million in Q2 2025, and -$4.7 million in Q1 2025.